Bentham Science Logo

Current Pharmacogenomics and Personalized Medicine

Formerly: Current Pharmacogenomics

Volume 17, 3 Issues, 2019
ISSN: 1875-6913 (Online)
ISSN: 1875-6921 (Print)
This journal supports open access

Aims & Scope

Current Pharmacogenomics and Personalized Medicine (CPPM) is a transdisciplinary peer-reviewed biomedical journal that reports new findings and cutting-edge concepts in both pharmacogenomics and personalized medicine under a single cover. CPPM is an accelerator for global personalized medicine and pharmacogenomics. Importantly, the journal provides a multi-disciplinary integrated platform from cell to society to address diagnostics and responsible pharmacogenomics applications in developing countries.

CPPM cooperates with the Ibero-American Network of Pharmacogenetics and the Pacific Rim Association for Clinical Pharmacogenetics and welcomes peer reviewed contributions from qualified authors in any global region including the Central and Latin American countries, Asia-Pacific and developing countries.

The Journal scope is defined by three inter-connected aims. First, we are interested in genomics/postgenomics biotechnologies and diagnostics that enable global personalized medicine science (including and beyond pharmacogenomics) as long as they explain person-to-person and population differences in disease susceptibility or response to a health intervention, and they can be mechanistically substantiated. Second, we approach personalized medicine as ‘personalized health interventions’ focusing primarily on drug therapy, but also other interventions such as nutrition, vaccines, surgical devices, emerging cell-based therapies that collectively contribute to healthcare. Third, we strive to integrate molecular and clinical investigation with public policy, global health diplomacy and social studies of biotechnology that collectively shape postgenomics future(s) and innovation trajectories in life sciences. Priority will be given to expert reviews/ mini-reviews and research articles that include original ideas and findings related to the journal scope and mandate.

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics)

,

Volume 16

-

Number 3



Biography   Open Access



Review Article   Open Access



Review Article   Open Access



Review Article   Open Access



Research Article   Open Access



Research Article   Open Access



Research Article



Acknowledgement   Open Access



Articles Ahead of Print




Genetic Polymorphisms of CYP2D6: Prevalence in Healthy Kurds


Muslih Abdulkarim Ibrahim*, Zalina Zahari*, Nurfadhlina Musa and Khoo Boon Yin


DOI: 10.2174/1875692117666190416145331
View Abstract


HLA-B27 is a Risk Factor for Rheumatoid Arthritis: Suggestion for an Evidence-based Update


Seyyed Amir Yasin Ahmadi, Reza Mohammadrezaei-Khorramabadi, Saber Abbaszadeh, Jafar Rezaian and Farhad Shahsavar*


DOI: 10.2174/1875692117666190408113012
View Abstract



Abstracts Ahead of Print

There are currently no Abstracts Ahead of Print available for this journal.

Published Contents

Editor's Choice



The Gut Microbiota in Cardiovascular Diseases: From Biomarkers and Potential Targets to Personalized Interventions

, 2018; 16(1): 75 - 85

Yaroslav I. Ashikhmin, Abram L. Syrkin, Andrey A. Zamyatnin Jr.*, Yong Zhang and Philipp Yu. Kopylov*


DOI: 10.2174/1875692116666180511170329




Cardiovascular Pharmacogenomics

, 2017; 15(1): 67 - 80

Valentina Manzo*, Sara Tarallo, Teresa Iannaccone, Maria Costantino, Walter Filippelli and Amelia Filippelli


DOI: 10.2174/1875692115666170503124456



Gender Differences in Response to Therapy for Cardiovascular Diseases

, 2017; 15(1): 14 - 26

Corbi Graziamaria*, Ambrosino Immacolata, Komici Klara, Cellurale Michele, Lombardi Anna and Ferrara Nicola


DOI: 10.2174/1875692115666170508153322



Allele Frequencies of CYP2D6, CYP3A5 and DPYD Genes Polymorphisms in the Healthy Yakut Population

, 2016; 14(1): 50 - 55

Filipp F. Vasilyev, Diana A. Danilova, Vladimir S. Kaimonov, Yana V. Chertovskih and Nadezda R. Maksimova


DOI: 10.2174/1875692114666160801151257




Exome-wide pharmacogenomic analysis of response to thiopurines in inflammatory bowel disease patients

, 2015; 13(1): 61 - 67

William Zabala, Raquel Cruz, Manuel Barreiro-de Acosta, María Chaparro, Julián Panes, Ana Echarri, Maria Esteve, Daniel Carpio, Montserrat Andreu, Esther Garcia-Planella, Eugeni Domenech, Angel Carracedo, Javier P. Gisbert, Francisco Barros and on behalf of EIGA and ENEIDA investigators


DOI: 10.2174/1875692113666150813151413




Open Access Articles

HLA-B27 is a Risk Factor for Rheumatoid Arthritis: Suggestion for an Evidence-based Update

, 2019; 17: 1 - 4 (E-Pub Ahead of Print)

Seyyed Amir Yasin Ahmadi, Reza Mohammadrezaei-Khorramabadi, Saber Abbaszadeh, Jafar Rezaian and Farhad Shahsavar*




Genetic Polymorphisms of CYP2D6: Prevalence in Healthy Kurds

, 2019; 17: 1 - 8 (E-Pub Ahead of Print)

Muslih Abdulkarim Ibrahim*, Zalina Zahari*, Nurfadhlina Musa and Khoo Boon Yin




Peculiaritie of Distribution of Polymorphic Variants of IL1Β Gene in Patients with Atherosclerosis and Metabolic Syndrome

, 2019; 17: 1 - 8 (E-Pub Ahead of Print)

Saranchina Yu.V*, Rossova NA, Khanarin NV, Kilina O. Yu, Dutova SV and Kulakova TS





Pharmacokinetics and Systems Pharmacology of Anti-CD47 Macrophage Immune Checkpoint Inhibitor Hu5F9-G4

, 2019; 17: 1 - 11 (E-Pub Ahead of Print)

Adarsh Mishra, Ishant Kataria and Sujit Nair*




Mutation Analysis of ABL1 Gene and its Relation to the Achievement of Major Molecular Response in Indonesian Chronic Myeloid Leukemia Patients

, 2019; 17: 1 - 7 (E-Pub Ahead of Print)

Reni Widyastuti, Ikhwan Rinaldi*, Melva Louisa, Riki Nova , SpFK Instiaty and Rizky Priambodo






Molecular Mechanism of Metformin Associated Lactic Acidosis (MALA)- an In Silico Exploration

, 2018; 16(3): 199 - 209

Siddiqur Rahman, Tamim Ahsan, Riajul Hossain, Tasnim Ahmed and Abu Ashfaqur Sajib*




Metabolomics-based Approach to Pharmacotherapy Personalization: Advantages and Limitations

, 2018; 16(3): 192 - 198

Dmitry L. Maslov*, Elena E. Balashova, Oxana P. Trifonova and Petr G. Lokhov






Individualized Cancer Therapy, Future Approaches

, 2018; 16(2): 156 - 163

Da-Yong Lu*, Ting-Ren Lu, Bin Xu, Jin-Yu Che, Ying Shen and Nagendra Sastry Yarla







Most Cited Articles






Clinical Trial

Individualized cancer therapy, future approaches

, 2018; 16(2): 156-163.

Da-Yong Lu*, Ting-Ren Lu, Bin Xu, Jin-Yu Che, Ying Shen and Nagendra Sastry Yarla


DOI: 10.2174/1875692116666180821095434



General Review Article

The gut microbiota in cardiovascular diseases: From biomarkers and potential targets to personalized interventions

, 2018; 16(1): 75-85.

Yaroslav I. Ashikhmin, Abram L. Syrkin, Andrey A. Zamyatnin Jr*, Yong Zhang and Philipp Yu. Kopylov*


DOI: 10.2174/1875692116666180511170329


Research Article

Molecular mechanism of metformin associated lactic acidosis (MALA)-an in silico exploration

, 2018; 16(3): 199-209.

Siddiqur Rahman, Tamim Ahsan, Riajul Hossain, Tasnim Ahmed and Abu Ashfaqur Sajib*


DOI: 10.2174/1875692117666181207121639


Review Article

Metabolomics-based approach to pharmacotherapy personalization: Advantages and limitations

, 2018; 16(3): 192-198.

Dmitry L. Maslov*, Elena E. Balashova, Oxana P. Trifonova and Petr G. Lokhov


DOI: 10.2174/1875692116666181008144905








Most Accessed Articles






The Gatekeeping Function in Personalized Medicine Initiatives

, 2016; 14(1): 36-49.

Gratien Dalpe, Emily Kirby, Ida Ngueng Feze, Anne-Marie Tasse, Bartha M. Knoppers, Pavel Hamet, Johanne Tremblay, Michael S. Phillips and Yann Joly


DOI: 10.2174/187569211401170116202755








Editor-in-Chief

Ramón Cacabelos
Institute of Medical Science and Genomic Medicine
Corunna
Spain

Biography View Full Editorial Board

Journal History

Current Pharmacogenomics was launched in 2003 and later renamed in 2008 as Current Pharmacogenomics and Personalized Medicine.

Related Journals

Related eBooks

eBooks Catalog